Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma

Journal of Investigative Dermatology

Volumn 137, Issue 1, 2017, Pages 159-169

  Lucarini, Valeria ^a   Buccione, Carla ^a   Ziccheddu, Giovanna ^a   Peschiaroli, Francesca ^a   Sestili, Paola ^a   Puglisi, Rossella ^a   Mattia, Gianfranco ^a   Zanetti, Cristiana ^a   Parolini, Isabella ^a   Bracci, Laura ^a   Macchia, Iole ^a   Rossi, Alessandra ^a   D'Urso, Maria Teresa ^a   Macchia, Daniele ^a   Spada, Massimo ^a   De Ninno, Adele ^b   Gerardino, Annamaria ^b   Mozetic, Pamela ^c   Trombetta, Marcella ^c   Rainer, Alberto ^c   Businaro, Luca ^b,c   Schiavoni, Giovanna ^a   Mattei, Fabrizio ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CNR   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CD11B ANTIGEN; CD8 ANTIGEN; CXCL9 CHEMOKINE; DECITABINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; INTERLEUKIN 12; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1; AZACITIDINE; INTERFERON;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL HOMING; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EPIGENETICS; FEMALE; GENE; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MELANOMA CELL; MOUSE; MX1 GENE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; GENETICS; NONPARAMETRIC TEST; PATHOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON TYPE I; MELANOMA; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 85006746576     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.08.024     Document Type: Article

References (58)

1. Antonia, S.J., Larkin, J., Ascierto, P.A., Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res 20 (2014), 6258–6268.
2. Boussommier-Calleja, A., Li, R., Chen, M.B., Wong, S.C., Kamm, R.D., Microfluidics: a new tool for modeling cancer. Trends in Cancer 2 (2016), 6–19.
3. Bronte, V., Chappell, D.B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162 (1999), 5728–5737.
4. Burnette, B.C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N.N., Weichselbaum, R.R., et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71 (2011), 2488–2496.
5. Businaro, L., De Ninno, A., Schiavoni, G., Lucarini, V., Ciasca, G., Gerardino, A., et al. Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab Chip 13 (2013), 229–239.
6. Chevolet, I., Schreuer, M., Speeckaert, R., Neyns, B., Hoorens, I., van Geel, N., et al. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?. Melanoma Res 25 (2015), 357–361.
7. Chiappinelli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162 (2015), 974–986.
8. Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208 (2011), 1989–2003.
9. Dubrot, J., Palazon, A., Alfaro, C., Azpilikueta, A., Ochoa, M.C., Rouzaut, A., et al. Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer 128 (2011), 105–118.
10. Dunn, G.P., Koebel, C.M., Schreiber, R.D., Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 (2006), 836–848.
11. Fratta, E., Sigalotti, L., Covre, A., Parisi, G., Coral, S., Maio, M., Epigenetics of melanoma: implications for immune-based therapies. Immunotherapy 5 (2013), 1103–1116.
12. Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208 (2011), 2005–2016.
13. Fujimura, T., Okuyama, R., Ohtani, T., Ito, Y., Haga, T., Hashimoto, A., et al. Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol 34 (2009), 793–799.
14. Gajewski, T.F., Louahed, J., Brichard, V.G., Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16 (2010), 399–403.
15. Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med, 9, 2011, 204.
16. Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Slingluff, C., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69 (2009), 3077–3085.
17. Ji, R.-R., Chasalow, S.D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61 (2012), 1019–1031.
18. Jiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T.J., Utikal, J., et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer 136 (2015), 2352–2360.
19. Kakizaki, A., Fujimura, T., Furudate, S., Kambayashi, Y., Yamauchi, T., Yagita, H., et al. Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. Oncoimmunology, 4, 2015, e1047584.
20. Kang, D.C., Gopalkrishnan, R.V., Wu, Q., Jankowsky, E., Pyle, A.M., Fisher, P.B., mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 99 (2002), 637–642.
21. Karpf, A.R., Peterson, P.W., Rawlins, J.T., Dalley, B.K., Yang, Q., Albertsen, H., et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci USA 96 (1999), 14007–14012.
22. Kaufman, H.L., Mehnert, J.M., Davar, D., Kirkwood, J., Adjuvant therapy of melanoma. Melanoma 167 (2015), 181–208.
23. Lee, J.J., Murphy, G.F., Lian, C.G., Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest 94 (2014), 822–838.
24. Li, X., Mei, Q., Nie, J., Fu, X., Han, W., Decitabine: a promising epi-immunotherapeutic agent in solid tumors. Expert Rev Clin Immunol 11 (2015), 363–375.
25. Lim, J.Y., Gerber, S.A., Murphy, S.P., Lord, E.M., Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63 (2014), 259–271.
26. Lorenzi, S., Mattei, F., Sistigu, A., Bracci, L., Spadaro, F., Sanchez, M., et al. Type I IFNs control antigen retention and survival of CD8{alpha}+ dendritic cells afteruptake of tumor apoptotic cells leading to cross-priming. J Immunol 186 (2011), 5142–5150.
27. Lowder, J.N., Taverna, P., Issa, J.P., Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?. Epigenomics 7 (2015), 1083–1088.
28. Mattei, F., Schiavoni, G., De Ninno, A., Lucarini, V., Sestili, P., Sistigu, A., et al. A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. J Immunotoxicol 11 (2014), 337–346.
29. Micali, O.C., Cheung, H.H., Plenchette, S., Hurley, S.L., Liston, P., LaCasse, E.C., et al. Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta. BMC Cancer, 7, 2007, 52.
30. Momparler, R.L., Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol 42 (2005), S9–S16.
31. Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R.P., Kalinski, P., PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71 (2011), 7463–7470.
32. Pace, L., Vitale, S., Dettori, B., Palombi, C., La Sorsa, V., Belardelli, F., et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol 184 (2010), 5969–5979.
33. Pinto, A., Zagonel, V., 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 7:Suppl 1 (1993), 51–60.
34. Prieto, P.A., Reuben, A., Cooper, Z.A., Wargo, J.A., Targeted therapies combined with immune checkpoint therapy. Cancer J 22 (2016), 138–146.
35. Rafique, I., Kirkwood, J.M., Tarhini, A.A., Immune checkpoint blockade and interferon-alpha in melanoma. Semin Oncol 42 (2015), 436–447.
36. Reu, F.J., Bae, S.I., Cherkassky, L., Leaman, D.W., Lindner, D., Beaulieu, N., et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 24 (2006), 3771–3779.
37. Rossi, Ú.A., Finocchiaro, L.M., Glikin, G.C., Interferon-β gene transfer inhibits melanoma cells adhesion and migration. [e-pub ahead of print] Cytokine, 2015 http://dx.doi.org/10.1016/j.cyto.2015.11.012.
38. Saleh, M.H., Wang, L., Goldberg, M.S., Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother 65 (2016), 787–796.
39. Schiavoni, G., Mattei, F., Gabriele, L., Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response. Front Immunol, 4, 2013, 483.
40. Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 71 (2011), 768–778.
41. Sharabi, A.B., Lim, M., DeWeese, T.L., Drake, C.G., Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 (2015), e498–e509.
42. Siren, J., Pirhonen, J., Julkunen, I., Matikainen, S., IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 174 (2005), 1932–1937.
43. Tarhini, A.A., Butterfield, L.H., Shuai, Y., Gooding, W.E., Kalinski, P., Kirkwood, J.M., Differing patterns of circulating regulatory T-cells and myeloid derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother 35 (2012), 702–710.
44. Thomas, X., DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opin Drug Discov 7 (2012), 1039–1051.
45. Timp, W., Feinberg, A.P., Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 13 (2013), 497–510.
46. Tissari, J., Siren, J., Meri, S., Julkunen, I., Matikainen, S., IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol 174 (2005), 4289–4294.
47. Tovey, M.G., Begon-Lours, J., Gresser, I., A method for the large scale production of potent interferon preparations. Proc Soc Exp Biol Med 146 (1974), 809–815.
48. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
49. Umansky, V., Sevko, A., Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 22 (2012), 319–326.
50. Vacchelli, E., Ma, Y., Baracco, E.E., Sistigu, A., Enot, D.P., Pietrocola, F., et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350 (2015), 972–978.
51. Van der Jeught, K., Joe, P.T., Bialkowski, L., Heirman, C., Daszkiewicz, L., Liechtenstein, T., et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-beta and the ectodomain of the TGF-beta receptor II potentiates antitumor immunity. Oncotarget 5 (2014), 10100–10113.
52. Weintraub, K., Take two: combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med 22 (2016), 8–10.
53. Wenzel, J., Bekisch, B., Uerlich, M., Haller, O., Bieber, T., Tuting, T., Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol 124 (2005), 37–48.
54. Zamarin, D., Postow, M.A., Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther 150 (2015), 23–32.
55. Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep, 6, 2016, 19103.
56. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat Rev Immunol 15 (2015), 405–414.
57. Zoglmeier, C., Bauer, H., Nörenberg, D., Wedekind, G., Bittner, P., Sandholzer, N., et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 17 (2011), 1765–1775.
58. Zou, L., Barnett, B., Safah, H., Larussa, V.F., Evdemon-Hogan, M., Mottram, P., et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 64 (2004), 8451–8455.